Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Constantine S Mitsiades, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Constantine Mitsiades and Jacob Laubach.
Connection Strength

2.369
  1. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib?+?dexamethasone in relapsed and relapsed/refractory multiple myeloma. Blood Cancer J. 2021 Feb 05; 11(2):20.
    View in: PubMed
    Score: 0.246
  2. Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Rep. 2021 Jan 05; 34(1):108532.
    View in: PubMed
    Score: 0.244
  3. Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51.
    View in: PubMed
    Score: 0.137
  4. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
    View in: PubMed
    Score: 0.131
  5. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
    Score: 0.128
  6. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May 10; 29(14):1916-23.
    View in: PubMed
    Score: 0.124
  7. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19.
    View in: PubMed
    Score: 0.123
  8. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60.
    View in: PubMed
    Score: 0.123
  9. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
    View in: PubMed
    Score: 0.122
  10. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
    View in: PubMed
    Score: 0.112
  11. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009 Dec; 23(12):2222-32.
    View in: PubMed
    Score: 0.111
  12. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
    View in: PubMed
    Score: 0.111
  13. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
    View in: PubMed
    Score: 0.108
  14. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052.
    View in: PubMed
    Score: 0.053
  15. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
    View in: PubMed
    Score: 0.041
  16. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
    View in: PubMed
    Score: 0.041
  17. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37.
    View in: PubMed
    Score: 0.036
  18. New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66.
    View in: PubMed
    Score: 0.035
  19. Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012; 4:253-68.
    View in: PubMed
    Score: 0.034
  20. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
    View in: PubMed
    Score: 0.033
  21. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
    View in: PubMed
    Score: 0.033
  22. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
    View in: PubMed
    Score: 0.032
  23. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
    View in: PubMed
    Score: 0.032
  24. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
    View in: PubMed
    Score: 0.031
  25. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79.
    View in: PubMed
    Score: 0.031
  26. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
    View in: PubMed
    Score: 0.029
  27. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
    View in: PubMed
    Score: 0.029
  28. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
    View in: PubMed
    Score: 0.029
  29. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010 Feb; 8 Suppl 1:S4-S12.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.